RE:RE:RE:RE:RE:RE:Those expecting a rabbit on January 19 will be disappointedI would class that as a wrong decision add to the list of wrong decisions ignoring the retail investors, only relying on analysts to get better valuation( Ed Nash failed miserably), going after only institutional investors when obviously so far there hasn't been any luck there and even there is some interest they can't due to low valuation, constructing a appealing website presenting both protocols and the their drugs which also clearly shows they are open for partnership( in case they wanted to choose that route), not to mention having members of the upper management still working for the company "while stuck in his house".
SPCEO1 wrote: They certainly are not crooked and they have run the company well otherwise, so they also do not seem stupid. But all of us are prone to make foolish decisions from time to time.
palinc2000 wrote: I dont see crooked behaviour but I do see sloppy work ....I am sure that they saw stumbling bkocks weeks before the deal was announced but were unable to circumvent...Paul s expertise is in every facet of a company except financing,,,Next tome there will be a diferent CFO and or they will hire a financial advisor
qwerty22 wrote: But that seems to leave no rational explanation for the deal other than crooked behaviour or outright stupidity.
SPCEO1 wrote: I am pretty sure that due to the massive bubble we are in, if I went to Wall Street with a deal to sell tomatoes on the street corner by taking orders over the internet, I could get financed. I mean, really, take a look around and see the nonsense that is getting financed on good terms right now. Then look at comparable companies in the NASH space and see the deals they have done in the not too distant past. Sure, TH should not get those valuations yet due to the data questions but the discount they are getting is jst way too massive. Then they applied another huge discount to that to price this offering after waiting only two days to let the reality that TH was a phase III NASH player sink in to the average investor's psyche!
If this was the only deal on the table for the company, or the best deal, somebody is simply not doing a very good job at searching at deals. You really would struggle to find a better time to get good deal terms than now. Remember too that the RBC convertible offering has left us with an analyst who seemingly hates the company he helped raise $57.5 million for - very, very odd. (BTW, you may remember I thought that was a brilliant deal so don't listen to those who say I hate any financing the company does). The track record speaks for itself and it is not pretty.
qwerty22 wrote: "The only thing they can say is that was the only offer on the table"
That unfortunately might be the reality.
palinc2000 wrote: There is no way they can sugar coat this bad deal...The only thing they can say is that was the only offer on the table and they wanted to secure the financing before undertaking clinical trials,
The objective was right but the path to reach it is a disaster, I dont think there are any other ways to describe this deal